Combination of aurora kinase inhibitors and anti-CD20 antibodies
US10391100B2 · kind B2 · utility
0Cited by
18References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 22, 2016 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Dec 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.